residential training - qut · the bridge prgram // residential training // #bridgeprogram2018 7 dr...

RESIDENTIAL TRAINING28th, 29th, 30th October 2018

Macquarie University and Curzon Hall, Sydney NSW

The Bridge Program has received industry-matched funding through the MTPConnect Project Fund Program – investing in ideas to

improve the productivity, competitiveness and innovative capacity of Australia’s medtech, biotech and pharmaceutical sector.

T R A N S F E R R I N G S K I L L S O N T H E C O M M E R C I A L I S AT I O N

O F P H A R M A C E U T I C A L R E S E A R C H

LinkedIn The Bridge Program: @The-Bridge-Program

The Bridge Program Participants: @The-Bridge-Program-Group

Twitter: @program_bridge

#BridgeProgram2018

https://twitter.com/program_bridge

https://www.linkedin.com/company/the-bridge-program/

https://www.linkedin.com/groups/13519991/

Dear Bridge Program participants

Welcome to the Bridge Program Residential Training Program! You are part of the second cohort to enter this

program, which is an important part of the overarching Bridge Program.

I encourage you to take full advantage of The Bridge Program and its many opportunities to collaborate and to

learn practical skills directly from practitioners with proven success in the pharmaceutical sector. In these three

days you will have the chance to enhance your commercialisation and business-management skills and ask

questions of the brightest minds in the pharmaceutical sector in Australia.

MTPConnect is a proud supporter of the Bridge Program, which has delivered outstanding training to 199

participants since its launch in June 2017. Its objectives are similar to ours - bring together industry, research

organisations and universities to address the skills-gap and drive collaboration and commercialisation.

Over the next few days of face-to-face training you will be provided with the perfect opportunity to network with

your fellow participants, the 15 consortia members (without whom The Bridge Program wouldn’t be possible), and

a range of key national and international guests.

It has been fantastic to see such a broad range of participants this year who take to this program so

enthusiastically, and I have no doubt that the program and you - the graduating participants - will make positive

contributions to the future of the MTP sector in Australia. We look forward to celebrating your future successes!

Yours sincerely,

Dr Dan Grant

CEO

THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018 3

W E L C O M E

BRIDGE PROGRAM SYMPOSIUMTHE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram20184

SUNDAY, 28 OCTOBER, MACQUARIE UNIVERSITY

How the global pharmaceutical industry discovers and develops drugs

TIME SESSION PRESENTER CHAIR

08:00 – 09:00 Registration

09:00 - 09:10 Presentation: Welcome to The Bridge Program Sue MacLeman, MTPConnect My Linh Kha, Amgen

09:10 – 09:20 Presentation: Outline of the Residential Program Lyn Griffiths, QUT My Linh Kha, Amgen

09:20 – 09:50 Presentation: The Evolution of Pharmaceutical Sue MacLeman, MTPConnect Lyn Griffiths, QUT Discovery, Development and Commercialisation in Australia

09:50 – 10:40 Presentation: Understanding the Pharmaceutical Garnet Howells, Amgen My Linh Kha, Amgen Development Pathway - What Drives Discovery and Investment Decisions?

10:40 – 11:00 Morning tea

11:00 – 11:30 Presentation: The Path to an Investigational Ed Lobenhofer, Amgen Sean Lybrand, Amgen New Drug (IND)

11:30 – 12:00 Presentation: Due Diligence and IP Real life Rob McInnes, IP Advisory Sean Lybrand, Amgen Licensing from the Trenches Goslik Schepers, Brandon Capital Partners

12:00 – 12:30 Biotech Commercialisation and Collaboration Rob McInnes, IP Advisory Phil Kearney, MSD Experience: Orientation Goslik Schepers, Brandon Capital Partners

12:30 – 13:30 Lunch & Networking

13:30 – 15:00 Biotech Commercialisation and Collaboration Rob McInnes, IP Advisory Laura Issa, AbbVie Experience: Framing a Potential Deal and Establishing your ‘Ask’

15:00 – 15:30 Afternoon tea

15:30 – 16:00 Presentation: How Global Pharmaceutical Elizabeth Kowaluk, AbbVie David Thomson, AbbVie Companies Decide Where to Invest

16:00 – 16:30 Presentation: How to Optimise your Interactions Shankar Subramanian, AbbVie David Thomson, AbbVie with Global Pharma

16:30 – 17:00 Panel Session: The Patient at the Centre: Driving Garnet Howells, Amgen David Thomson, AbbVie Innovation to Optimise Outcomes Ed Lobenhofer, Amgen Elizabeth Kowaluk, AbbVie Maryjo Chamberlain, AbbVie

17:00 – 18:30 Speed Networking, Drinks and Canapes

DAY 1

BRIDGE PROGRAM SYMPOSIUMTHE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018 5


09:00 – 09:10 Recap of Day 1, Overview of Day 2 Lyn Griffiths, QUT Agenda and Biotech Commercialisation and Collaboration Experience Activities

09:10 – 09:50 Presentation: Early Clinical Development Charmaine Gittleson, CSL Anne-Maree Englund, MSD

09:50 – 10:20 Case Study: An Early Trial Garnet Howells, Amgen Anne-Maree Englund, MSD

10:20 – 10:50 Case Study: Global Development of New Medicines Bill Lam, Pfizer Anne -Maree Englund, MSD


11:20 – 11:40 Presentation: Digital Innovation: Transforming Patrick Dey, Amgen Peter Germanos, Boehringer Healthcare Ingelheim

11:40 – 12:00 Presentation: The Future of Digital Health Bill Taranto, Merck Innovation Fund Peter Germanos, Boehringer Ingelheim

12:00 – 12:30 Panel Session: Digital Health Patrick Dey, Amgen Peter Germanos, Boehringer Bill Taranto, Merck Innovation Fund Ingelheim Bronwyn Le Grice, ANDHealth

12:30 – 13:00 Lunch

13:00 – 13:40 Case Study: Positioning Successfully Deborah Rathjen, Bionomics Anand Gautam, Pfizer

13:40 – 14:10 Presentation: Raising Capital – Australian Perspective Melissa McBurnie, Brandon Anand Gautam, Pfizer Capital Partners

14:10 – 14:40 Panel Discussion: Raising Capital - Melissa McBurnie, Brandon Anand Gautam, Pfizer International Perspectives Capital Partners Deborah Rathjen, Bionomics Paul Kelly, OneVentures Bill Taranto, Merck Innovation Fund


15:00 – 16:30 Biotech Commercialisation and Collaboration Rob McInnes, IP Advisory Meriana Baxter, Mundipharma Experience: Refining a Pitch and Crafting a Deal

16:30 – 17:00 Case Study: Pharmaxis – Facing Early Challenges and Gary Phillips, Pharmaxis Meriana Baxter, Mundipharma Implementing a Successful Turnaround Strategy

17:00 – 18:30 Break Before Dinner

18:30 – 19:00 Pre-Dinner Drinks

19:00 – 22:30 Networking Dinner and Announcement of Pitch Winners

MONDAY, 29 OCTOBER, CURZON HALL

Bench to BiotechDAY

2

BRIDGE PROGRAM SYMPOSIUMTHE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram20186


09:00 – 09:10 Recap of Day 2, Overview of Day 3 Lyn Griffiths, QUT Agenda and Simulation Activities

09:10 – 09:40 Presentation: How the Australian Government Charlie Day, Innovation and Lyn Griffiths, QUT Supports Life Science Sector Science Australia

09:40 – 10:30 Presentation: Realising the Value of Medicines Martin Zagari, Amgen Lyn Griffiths, QUT in Healthcare and Society


10:50 – 11:10 Presentation: Navigating National and International Helen Critchley, Sanofi Sean Lybrand, Amgen Regulatory Approval

11:10 – 11:30 Presentation: Evidence Generation for Regulatory Petra Moroni-Zentgraf, Boehringer Sean Lybrand, Amgen and Reimbursement Approvals Ingelheim

11:30 – 12:00 Panel Discussion: The Challenges of Martin Zagari, Amgen Sean Lybrand, Amgen Reimbursement and Realising the Value of Petra Moroni-Zentgraf, Boehringer Medicine into the Future Ingelheim Helen Critchley, Sanofi

12:00 – 12:30 Lunch

12:30 – 13:00 Case Study: Pivoting for Success: The Story Megan Baldwin, Opthea My Linh Kha, Amgen of Opthea

13:00 – 13:30 Presentation: A Career in the Australian Stewart Washer, My Linh Kha, Amgen Life Science Industry Zelda Therapeutics Pty

13:30 – 14:00 Evaluation: Independent Evaluation Session Kylie Birkinshaw, QUT Cynthia Cliff, QUT

14:00 – 15:00 Biotech Commercialisation and Collaboration Rob McInnes, IP Advisory Meriana Baxter, Mundipharma Experience: Culmination and Learnings: Goslik Schepers, Brandon Capital Partners Panel Session with the Judges Brett Roberts, Novartis Ingmar Wahlqvist, Brandon Capital Partners Melissa McBurnie, Brandon Capital Partners Paul Kelly, OneVentures Alfredo Martinez-Coll, MTPConnect Sean Lybrand, Amgen


15:30 – 15:50 Presentation: Program Wrap Up Lyn Griffiths, QUT

15:50 – 16:00 Formal Close Mr John Alexander MP Lyn Griffiths, QUT Member for Bennelong

16:00 – 17:00 Networking & Closing Drinks

BRIDGE PROGRAM SYMPOSIUM

TUESDAY 30 OCTOBER, MACQUARIE UNIVERSITY

Biotech to PatientDAY

3

B I O G R A P H I E S7THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018

Dr Megan Baldwin CEO and Managing Director, Opthea Limited

Megan Baldwin, PhD is CEO and Managing Director of Opthea Limited, a public company listed on the ASX. Dr Baldwin has over 20 years of experience focussing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications. Dr Baldwin joined Opthea in 2008 and has held various positions, including Head of Preclinical R&D and Chief Executive Officer of Opthea Pty Ltd, which at that time operated as a 100% owned subsidiary of Circadian (now Opthea Limited), developing OPT-302 for the treatment of wet age-related macular degeneration. Prior to Opthea, she was employed at Genentech (now Roche), the world leader in angiogenesis-based therapies for cancer and other diseases. Her experience includes several years as a researcher in the group of leading angiogenesis expert Napoleone Ferrara, before moving to Genentech’s commercial division in the market planning department. In these roles, she developed extensive commercial and scientific knowledge in anti-angiogenic and oncology drug development. Dr Baldwin holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research and is a member of the Australian Institute for Company Directors and a director of AusBiotech.

Meriana Baxter Director of Corporate Affairs and Communications, Mundipharma

Meriana Baxter has 25 years’ experience in policy development, stakeholder engagement, corporate communications and government engagement in financial services, infrastructure, telecommunications and healthcare. Ms Baxter is passionate about bringing people together for good outcomes, explaining in large part her commitment to The Bridge Program.

Kylie Birkinshaw Academic Coordinator – The Bridge Program // Lecturer and Unit Coordinator, Queensland University of Technology

Kylie Birkinshaw is an Academic Coordinator, Lecturer and Unit Coordinator at Queensland University of Technology. She has had a varied career in education, science and pharmacy and held previous roles at the University of Queensland in the School of Pharmacy, Murdoch University in Western Australia and the National Prescribing Service.

Ms Birkinshaw is a registered pharmacist and has a keen interest in increasing collaboration between academia and industry to enhance commercialisation of Australia’s pharmaceutical research.

Her current role is the Academic Coordinator for the MTPConnect funded Bridge Program, an industry led initiative unique in its integration into venture capital and global pharmaceutical networks designed to enhance and accelerate the process of commercialisation.

B I O G R A P H I E S8 THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018

Dr Cynthia Cliff Director (Knowledge Transfer and Partnership Development), Queensland University of Technology

Cynthia Cliff is the Director (Knowledge Transfer and Partnership Development) in the Faculty of Health at Queensland University of Technology (QUT) in Brisbane, Australia. This pioneering role, in academic terms, reflects a career-long fascination with innovation at the industry-academic interface.

Prior to joining QUT’s Faculty of Health, Dr Cliff assisted government, the private sector and NGOs with business innovation across a diversity of industries ranging from mining to the arts and space technology. She has also worked with the government examining future directions in tertiary education, and with the consumer movement on the impact of manufacturing and marketing practice on consumer health and the environment.

At QUT Dr Cliff’s enterprise, international and engagement skills have contributed to the university’s ability to solve real world problems by actively fostering multidisciplinary and inter-professional teaching and research in the Faculty of Health. Her passion for innovation and active promotion of deep, enduring and mutually beneficial international and industry collaboration has contributed significantly to QUT’s long-term relationships in Australia, PR China, Vietnam, Indonesia, Finland and the UK.

Dr Helen Critchley Country Regulatory Head, Sanofi

Helen Critchley is Country Regulatory Head at Sanofi responsible for Australia and NZ and Industry Co-Chair of the Medicines Australia Regulatory Affairs Working Group. She is a qualified pharmacist with degree in pharmacy from the University of Bath and a PhD from the University of Nottingham in the UK. Dr Critchley has had over 25 years in the pharmaceutical industry initially in R&D working in formulation development and manufacturing and subsequently Regulatory Affairs. She has broader experience in global drug development from startup biotech to large pharma organisations across a range of therapeutic areas as well as expertise across a diverse product portfolio including biologicals, vaccines, devices, orphan drugs, OTC and complementary medicines.

Dr Critchley has an established track record of successful liaison and negotiation with global regulatory agencies, to obtain marketing authorisations in EU, Australia, NZ and other major territories outside of the US. She is also an active member of industry groups in Australia and NZ working in partnership with government to create an optimal framework that protects public health and supports innovation.

Dr Maryjo Chamberlain Senior Director and Global Head of Academics and External Innovation Scouting in Search and Evaluation, AbbVie

As Senior Director and Global Head of Academics and External Innovation Scouting in Search and Evaluation, Dr. Chamberlain is responsible for Academic Outreach and Relationship Management across academic and research institutions as well as non-profit foundations across the globe for all of AbbVie’s Therapeutic and Functional areas. Her role encompasses identifying assets, technologies, capabilities and capacities from early discovery phase through all phases of preclinical and clinical development.

Dr. Chamberlain also leads AbbVie’s Global Scouting Team to identify all forms of external innovation within AbbVie’s Core Therapeutic and Strategic Areas. She has a PhD in Neuroscience and an MBA in Finance/Marketing. Dr Chamberlain joined AbbVie approximately 4 years ago in this newly created role which speaks to AbbVie’s dedication to leveraging and nurturing relationships in this space. During her time at AbbVie, she has led the execution of multiple collaborations.

Prior to AbbVie, Dr. Chamberlain was at Eli Lilly for 17 years where she headed up Neuroscience Global External Research and Development. Dr. Chamberlain was also head of all East Coast Operations in Global External Research and Development across all the relevant therapeutic areas.

B I O G R A P H I E S9THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018

Dr Charlie Day CEO, Office of Innovation and Science Australia (OISA)

Charlie Day is the CEO of Innovation and Science Australia (ISA). He brings to the role significant expertise in innovation, business development, technology commercialisation, venture capital and start-up creation. As CEO, Dr Day leads the Office of Innovation and Science Australia and supports the Innovation and Science Australia (ISA) board’s implementation of long-term initiatives to boost Australia’s innovation, science and research system.

ISA provides strategic, whole-of-government advice on all science, research and innovation matters. In January 2018 ISA released the Australia 2030: Prosperity through Innovation report, which sets out a path for Australia to become a leading innovation nation by 2030.

Immediately prior to taking up his role with ISA, Dr Day was the Program Director for the Carlton Connect Initiative, an ambitious project to create Australia’s premier STEM innovation precinct anchored by the University of Melbourne.

Patrick Dey

Vice President, Digital Health & Innovation, Amgen

Patrick Dey, was recently named as Vice President of Digital Health and Innovation, Amgen, the world’s largest biotechnology company located in Thousand Oaks, CA. In his new role he is responsible for shaping and advancing Amgen’s Global Digital Health and Data strategy, with responsibility for delivering cross functional “beyond the molecule” strategy extending Digital Health capabilities.

For the past year, Mr Dey has been leading Digital Transformation at Amgen, focusing on unlocking insights and next generation digital and artificial intelligence technologies, as well as partnering with the commercial brand teams to enable and accelerate Amgen’s growth transformation using technology to enhance the patient journey.

Previously, Mr Dey led and established an IT Strategy and transformation supporting Amgen’s Global Operations, Supply Chain and Process Development (PD) Organisation.

Prior to joining Amgen, Mr Dey spent four years as Vice President of Information Systems at Mattel Inc. supporting Global Operations, Supply Chain and Design and Development. During his time at Mattel, Mr Dey executed multiple board approved programs designed to simplify global manufacturing and product development.

Anne-Maree Englund Policy Manager, MSD

Anne-Maree Englund is passionate about using innovative technologies to improve health outcomes. An engineer by trade, she also has a master’s in public policy, and combines a thorough knowledge of product development with a strong understanding of the broader health and innovation policy landscape. She started her career at the medical device innovator Cochlear, has been the Operations Manager at health IT start up SmartWard, and is currently the Policy Manager at MSD.

B I O G R A P H I E S1 0 THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018

Dr Charmaine Gittleson

Chief Medical Officer, CSL Limited

Charmaine Gittleson is an internationally experienced pharmaceutical physician having worked in the biopharmaceutical industry for over 20 years. She joined CSL in 2005, initially based in Australia where she established a clinical safety and then a clinical development function.

From 2010 to 2017 Dr Gittleson was based in King of Prussia, Pennsylvania, USA where she was responsible for clinical development strategy and ultimately all global clinical research. She has overseen the clinical development of both seasonal and pandemic influenza vaccines as well as a number of biologics within the rare disease and orphan space, resulting in global registrations. Additionally she has experience establishing new R&D groups in Japan and China.

Since returning to Melbourne, in 2017 Dr Gittleson has assumed the global role of Chief Medical Officer for CSL. In this capacity she has responsibility for early development and oversees the benefit risk profile of CSL products across their life cycle.

Peter Germanos

Head of Market Access, Pricing and Outcomes Research, Boehringer Ingelheim Australia and New Zealand

Working within the market access and policy areas, Mr Germanos has over 20 years of experience with Boehringer Ingelheim. He is also currently a member of the Health Economics Working Group of Medicines Australia and has served on various Medicines Australia committees for over 15 years. Mr Germanos has also worked for Wellcome within its medical function for over three years before it was incorporated within Glaxo. Prior to working in the pharmaceutical industry, Mr Germanos managed a community pharmacy for almost 10 years.

Dr Anand Gautam

Senior Director and Head of External Science & Innovation, Australia, New Zealand & Southeast Asia, Pfizer

Anand Gautam has 25 years of leadership in R&D and innovation strategies in Inflammation/Autoimmune Diseases/Cancer at international biotech and pharmaceutical companies. In addition, Dr Gautam has spent over 12 years as an academic in Immunology in prestigious research centers in the UK (PhD at University of London), US (post-doc at Stanford University, California), and Australia (Academic positions at ANU, Canberra & UQ, Brisbane). Before joining Pfizer as a Head of External Science & Innovation, ANZ & Southeast Asia in April 2017, Dr Gautam was a Senior Director of R&D Innovation Sourcing at Novo Nordisk, Copenhagen for eight years. Prior to that, he was VP of R&D at Progen (Brisbane, Australia), and SVP of External Science & Collaboration at Pharmexa (Denmark).

Dr Gautam has obtained numerous grants to carry out his scientific research, including an NIH grant to work on novel adjuvants for bioterrorism vaccines in 2005; and a Career Development Award from Juvenile Diabetes Foundation International, USA. Dr Gautam has published numerous papers in peer-reviewed scientific journals and was awarded a Howard Florey Young Investigator’s Award at John Curtin School of Medical Research in 1996. Dr Gautam serves on a number of committees, is a Life Science Queensland Ambassador, and is an Adjunct Professor at The Institute for Molecular Biosciences, University of Queensland.

B I O G R A P H I E S1 1THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018

Professor Lyn Griffiths Executive Director, Institute of Health and Biomedical Innovation, Queensland University of Technology

Lyn Griffiths is the Executive Director of the Institute of Health and Biomedical innovation at QUT. She is a molecular geneticist who has been studying the genes involved in common human disorders for many years. Her expertise is in the field of human gene mapping and focuses on identifying the genes involved in common complex disorders, with a particular focus on neurogenetic disorders including migraine.

Professor Griffiths graduated from the University of NSW with Honours in Biochemistry and gained a PhD from the Faculty of Medicine, University of Sydney in 1990. Following her PhD she moved to Queensland where she established the Genomics Research Centre at Griffith University Gold Coast. Professor Griffiths was also Head of The School of Medical Science for many years, and held the role of Dean Research and Director of the Griffith Health Institute, before taking on the role as Executive Director of the Institute of Health and Biomedical Innovation at QUT. She has published over 320 research papers, supervised 46 Postgraduates and 45 Honours students and received significant competitive grant and industry funding. Professor Griffiths also plays a significant role in the Human Genetics Society of Australasia as a past Queensland President, convenor of a number of conferences and as the current Chair of the Diagnostic Genomics Board of Censors and Director of the new Masters in Diagnostics Genomics.

Garnet Howells Global Product General Manager, Cardiovascular, Amgen

Garnet Howells has worked for 20 years in the pharmaceutical industry. He has led cross-functional teams for global development of multi-modality (mAb, siRNA and small molecule) medicines across multiple therapy areas and throughout all stages of development (preclinical, Phase I, II, III and LCM development) in large and niche indications.

Mr Howells is focused on delivering and being part of the next wave of new therapies in disease areas where there are significant unmet needs.

Dr Laura Issa Business Development, Search and Evaluation - ANZ, AbbVie

Laura Issa is leading Business Development, Search and Evaluation in Australia and New Zealand for AbbVie, a global specialty biopharmaceutical company.

Dr Issa is passionate about life science, healthcare innovation, access equality and quality use of medicines. Dr Issa bridges science and business, having worked across the academic, biotechnology and pharmaceutical sectors, at all stages of the product life cycle to build value-based partnerships that advance medical research and innovation.

Prior to joining AbbVie, Dr Issa held Business Development and Licensing roles at Aspen Pharmacare and Merck Sharp Dohme, where she lead projects across all therapeutics areas and executed partnership deals with local, regional and global companies.

Prior to transitioning to the pharmaceutical industry, she was a senior technology transfer and licensing professional with NewSouth Innovations, and a published medical scientist at the Victor Chang Cardiac Research Institute. Dr Issa’s research interests included endocrinology, oncology, transcriptional gene regulation, epigenetics and stem cell biology.

Dr Issa achieved a PhD from the Garvan Institute of Medical Research (UNSW, 1999) and Master of Business Administration-Technology (UNSW; 2005). Dr Issa is a Graduate of the Australian Institute of Company Directors and sits on the Board of The Ruby Red Foundation.


My Linh Kha Executive Director and General Manager, Amgen Australia & New Zealand

My Linh Kha was appointed Managing Director, Amgen, Australia & New Zealand in December 2016 and has more than 20 years of broad international experience in both emerging and mature markets in the biopharmaceutical industry. Ms Kha’s expertise includes healthcare policy and pricing, building businesses in emerging markets, brand and organisation strategy, and she has particular strength in building and managing diverse teams.

Prior to joining Amgen Australia, Ms Kha spent more than two years as Executive Director Marketing for Amgen’s intercontinental region (Latin America, Canada, Turkey, Middle East & Africa), where she was responsible for the marketing of the general medicine therapeutic area, including bone, inflammation, cardiology, nephrology and digital marketing.

Ms Kha began her career with Amgen in early 2011 when she joined Amgen Australia as the Business Unit Director for General Medicine, and during this time she lead the team who launched and grew Amgen’s osteoporosis product, Prolia to market leadership.

Prior to joining Amgen, Ms Kha spent over seven years with Merck, Sharp and Dohme (MSD), during which time she held the roles of Commercial Operations Head in Korea, and Managing Director of MSD in Vietnam and Cambodia. Ms Kha received a Bachelor of Law and a Bachelor of Science from the University of Canterbury in New Zealand, and her early career involved marketing roles in both New Zealand and London.

Dr Paul Kelly Managing Partner, OneVentures

Paul Kelly is a Managing Partner of OneVentures and is a physician, researcher and biotechnology entrepreneur with over 25 years’ experience in founding, financing, developing and commercialising biomedical innovations in the USA, Europe, UK and Australia. Dr Kelly has founded and led early-stage and mid-stage companies to achieve business results in order to attract funding and transform their ideas, technologies and products into sustainable successful businesses. He has co-founded a number of other companies in the health sciences and technology arena, including Gemini Genomics (Nasdaq GMNI: later acquired by Sequenom in 2001), Atomera Inc (Nasdaq: ATMR), based in Los Gatos, California and AgaMatrix, Inc (a consumer medical device company), based in New Hampshire, USA. Dr Kelly is currently Chair of OneVentures, portfolio companies Vaxxas and Hatchtech and serves on the boards of FindMe Technologies, BiVacor and Clinical Genomics. Dr Kelly has served on a number of national governmental advisory bodies, as well as on the boards of public and private companies. He also serves on the Board of the Garvan Institute of Medical Research. Dr Kelly is a Fellow of the Australasian College of Physicians.

Dr Phil Kearney Director External Licensing, Merck Sharp & Dohme (MSD)

Phil Kearney joined MSD Australia in 2007 as the key scout for innovative research and development in the Asia Pacific region for India, South East Asia, Australia, & New Zealand. The Sydney-born scientist has the challenge of uncovering and commercialising discoveries by local researchers that have strong potential to benefit the health of people around the globe.

Dr Kearney is responsible for identifying partnership opportunities with research institutes and biotechnology companies to secure high-value intellectual property for the Merck & Co pipeline. Dr Kearney regularly liaises with Australian and New Zealand biotechnology companies and research institutes to look for new chemical and biological entities with therapeutic potential, validated drug targets and new platform technologies.

Dr Kearney’s extensive background in oncology and haematology is in keeping with one of MSD key focuses as the company looks to secure novel drug targets for cancer treatment and a range of other diseases. As an ambassador for regional science, he places a strong emphasis on his role in convincing international decision-makers within Merck of the worth of investing in Asia-Pacific health and medical research, especially Australian and New Zealand discoveries.


Dr Bill Lam Director, Clinical Site Management, Pfizer Australia & New Zealand

Bill Lam is Director, Clinical Site Management, Pfizer Australia & New Zealand. He joined Pfizer Australia as Associate Medical Director in 1999. Over the last 18 years, Dr Lam has taken up roles of increasing responsibility in Medical Affairs and Clinical Development. Dr Lam moved to Pfizer HQ, New York in 2004 as Regional Medical Director of Japan/Asia in cardiovascular medicine. In 2009, he became the Clinical Development Lead of Emerging Markets for medicines in the treatment of heart & thromboembolic diseases, pain, Alzheimer’s disease, and haemophilia. In 2012, Dr Lam was the Medical Affairs Lead of Asia, leading medical affairs initiatives for Pfizer’s innovative compound portfolio in internal medicine, inflammation & immunology and rare diseases. Dr Lam has recently returned to Australia to lead the Global Clinical Site Management team who delivers Phase 1-3 global clinical trials in Australia and New Zealand.

Dr Lam graduated in Medicine at the University of Bristol, United Kingdom, before receiving internal medicine training at Austin Health, Melbourne in Australia. Whilst being Fellow of Clinical Pharmacology at the University of Melbourne, he completed his PhD Medicine in the area of autonomic neuroscience. He was also a consultant clinical evaluator of pre-registered medicines for the Therapeutic Goods Administration.

Dr Elizabeth Kowaluk Senior Director, Search & Evaluation, AbbVie

Elizabeth Kowaluk is Senior Director, Search & Evaluation at AbbVie, a global research-driven biopharmaceutical company committed to developing innovative advanced therapies to address today’s health issues. Dr. Kowaluk’s responsibilities include initiatives and operations related to the search for external innovation, including the geographic operating model. Previously, Dr. Kowaluk has had leadership responsibilities in pharmaceutical discovery, portfolio and decision analysis, and corporate strategy. She holds a Ph.D. in Pharmaceutics, with postdoctoral experience in pharmaceutics and pharmacology.

Bronwyn Le Grice Managing Director, ANDHealth

Bronwyn Le Grice has 15 years executive experience in the health technology sector spanning venture capital, transaction management, capital raising, corporate development, investor relations and industry advocacy.

She is currently Managing Director of ANDHealth, a unique industry-led non-profit organisation focused on strengthening the Australia digital health ecosystem and de-risking innovations in digital health, with a focus on clinical evidence, commercialisation and investment readiness. As the Founding Managing Director, Ms Le Grice is also the chief architect of the ANDHealth+ program, which provides critical support to Australian mid-stage digital health companies to enable them to meet key investor, partner and customer requirements in relation to both clinical and commercial validation.

Prior to ANDHealth, Ms Le Grice held the role of Investment Director with leading Australian healthcare venture capital firm, BioScience Managers. She was responsible for managing significant transactions in the health technology & digital health sectors resulting in over A$65m of private and public equity raisings, including IPO’s on the Australia Stock Exchange and the UK Alternative Investments Market, in addition to participating in deal origination, due diligence and negotiation for two funds totalling A$96m under management.

Ms Le Grice is a Non-Executive Director of Imagion Biosystems Limited (ASX:IBX), a member of the Australian Institute of Company Directors, a member of Women on Boards and a member of the Australia New Zealand Leadership Forum Health Technologies Sector Group.


Sue MacLeman Chair and Non-Executive Director, MTPConnect

Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive with senior roles in corporate, medical, commercial and business development. Ms McLeman has also served as CEO and Board member of several ASX and NASDAQ listed companies in the sector and is currently Chair of Anatara Lifesciences Ltd, Chair of Novita Healthcare Ltd , Chair Elect and Non-Executive Director of MTPConnect (MTPII-GC Ltd), Non-Executive Director Oventus Medical Ltd, Imunexus and veski. Ms MacLeman is also appointed to a number of academic and government advisory committees. Her broad commercial experience is underpinned by graduate qualifications in pharmacy and post graduate qualifications in commercial law, corporate governance, business administration and marketing.

Sean Lybrand Director, Value, Access and Policy, Amgen

Sean Lybrand is leading a team of health economics, policy and government affairs experts in engagements on reimbursement and policy matters for Amgen in Australia and New Zealand.

Mr Lybrand has had a considerable breadth of career in academia and the pharmaceutical industry. Following on from his studies, Mr Lybrand moved to Sydney where he began working for Merck, Sharp & Dohme, and onto Merck & Co Inc (parent company of MSD). He subsequently became Regional Director of Vaccine Policy for Merck in the Asia Pacific region. His career highlight at Merck was establishing a country-wide vaccination program for human papillomavirus in the Kingdom of Bhutan, as a partnership with the Australian Cervical Cancer Foundation, Merck & Co Inc, and The Royal Government of Bhutan. Returning to Australia, Mr Lybrand established the market access and government affairs function at Biogen Australia Pty Ltd.

Mr Lybrand’s passion in health exists in seeking to improve health outcomes, he is committed to finding ways for governments, pharmaceutical companies, prescribers and health consumer organisations to work together for the most positive impacts for the community.

Dr Ed Lobenhofer Principal Scientist, Amgen

Ed Lobenhofer’s passion for positively affecting patients’ lives began in high school while volunteering at a local hospital in suburban Chicago. After obtaining an undergraduate degree in Biology Education, he earned a doctorate of philosophy in Cell and Molecular Biology from the Pathology Department at Duke University, conducting research on elucidating the molecular mechanisms underlying breast cancer.

The early part of Dr Lobenhofer’s scientific career concentrated on the then-burgeoning field of genomics and its application in identifying biomarkers of disease, as well as the field of toxicology. For the past 9 years, Dr Lobenhofer’s has worked at Amgen as a nonclinical safety scientist, developing preclinical safety packages for both small and large molecules in order to advance meaningful therapeutics in to the clinic.


Dr Melissa McBurnie Investment Manager, Brandon Capital Partners

Melissa McBurnie joined Brandon Capital Partners as an Investment Manager in 2008. Brandon Capital has over $500M under management and is a dedicated life science investment fund manager, investing from seed through to clinical stage assets. Dr McBurnie is a director of three start-up companies developing new therapeutics for cancer and metabolic disease.

Dr McBurnie started her investing career with Terra Rossa Capital in Adelaide, a fund manager specialising in seed-to-early stage life science investment. Previously, she was a Business Development Manager with Bio Innovation SA where she helped early stage companies refine their business plans and prepare to raise capital. Prior to joining Bio Innovation SA, Dr McBurnie worked in an early stage medical device company in Adelaide, assisting it with capital raising. She spent three years as a postdoctoral scientist at Prince Henry’s Institute of Medical Research, Victoria.

Dr McBurnie has a first class honours degree in science and PhD in Immunology from the University of Adelaide and an MBA, specialising in finance, from the University of South Australia. She also holds a Graduate Certificate in Applied Finance, is a graduate of the Australian Institute of Company Directors and a member of AusBiotech.

Rob McInnes CLP – Principal, Rob McInnes IP Advisory

Rob McInnes is the Principal of his solo practice Rob McInnes IP Advisory, which he founded after practising for 30 years in large law and patent attorney firms.

Mr McInnes specialises in intellectual property transactions, and advises clients on the management, commercialisation and enforcement of IP rights. He assists clients with planning, negotiating and drafting licensing and other IP agreements, and the setting up and financing of new technology ventures.

In addition to his career as a lawyer in private practice, Mr McInnes has a degree in chemistry and has been an in-house Manager of IP and Technology Transfer with a large company.

For most of the past decade Mr McInnes has been listed by Intellectual Asset Management Magazine as Australia’s most highly recommended patent and technology licensing lawyer. He is one of the few Australian lawyers to have met the requirements for the US-based Certified Licensing Professional qualification.

Dr Alfredo Martinez-Coll General Manager, Stakeholder Engagement, MTPConnect

Alfredo Martinez-Coll is a Graduate of the Australian Institute of Company Directors, a Registered Technology Transfer Professional and a member of the NSW AusMedTech (Medical Devices) Committee of AusBiotech. With a B.S. in Biomedical Engineering from Louisiana Tech University (USA), a PhD and post-doctoral training in biomedical sciences from University of Technology, Sydney, Dr Martinez-Coll brings more than 16 years research experience in the areas of artificial organs, cardiovascular and cerebrovascular physiology, membrane transport, and oxygen transport to tissue.

He has worked as a business development manager in Technology Transfer/commercialisation for the past 13 years at public hospitals and in academia. His main areas of interest are sustainable funding for science, entrepreneurship and innovation, project management in science and business development. Dr Martinez-Coll is passionate about engaging with researchers and Industry specialists in the Life Sciences arena to translate research discoveries into social impact. Prior to joining MTPConnect, Alfredo held the position of Senior Business Development Manager at UNSW Innovations.


Dr Deborah Rathjen CEO and Managing Director, Bionomics

Deborah Rathjen joined Bionomics in 2000 from Peptech Limited, where she was general manager of business development and licensing. Dr Rathjen was a co-inventor of Peptech’s TNF technology and leader of the company’s successful defence of its key TNF patents against a legal challenge by BASF.

Dr Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialisation. She has been recognised both in Australia and internationally through awards and honours including the 2004 AusBiotech President’s Medal, 2006 Flinders University Distinguished Alumni Award, 2009 BioSingapore Asia Pacific Biotechnology Woman Entrepreneur of the Year, 2009 Regional Finalist Ernst & Young, Young Entrepreneur of the Year, and 2014 Woman Executive of the Year BioPharm Industry Awards. In 2015 Dr Rathjen was included in the Top 50 most influential Australia business women by The Australian newspaper.

Gary Phillips Chief Executive Officer, Pharmaxis

Gary Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. After managing country operations for Swiss multinational pharmaceutical company Ciba Geigy and then Novartis in Eastern Europe and Asia, Mr Phillips came to Australia as CEO of Novartis in 2001. He joined Sydney based biotech company Pharmaxis in December 2003 when the company listed on the Australian Securities Exchange.

In the role of Chief Operating Officer he expanded Pharmaxis’ Commercial infrastructure in Europe and the USA, and supported the clinical development, regulatory approval and reimbursement of Pharmaxis products Aridol and Bronchitol. Aridol, an innovative lung function test, was the first Australian drug discovery to be approved by the US Food and Drug Administration. Bronchitol was the subject of two large scale clinical trials and is approved for the treatment of cystic fibrosis in Australia and Europe. Both products are produced at Pharmaxis’ approved high-tech manufacturing facility which now exports finished product to world markets.

Dr Petra Moroni Zentgraf Country Medical Director, Boehringer Ingelheim Australia and New Zealand

Family-owned and independent, Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies operating in over 50 countries with 50 000 staff globally. Since 1 June 2016, Dr Moroni-Zentgraf has held the position of Medical Director for Australia and New Zealand. Prior to this, as an internationally recognised expert in respiratory medicine and research; before her assignment in Australia Dr Moroni-Zentgraf held the role of Associate Therapeutic Area Head for Respiratory / Asthma & Cystic Fibrosis and Idiopathic Pulmonary Fibrosis / Interstitial Lung Disease within the department of Clinical Development and Medical Affairs for Boehringer Ingelheim globally.

Prior to her career at Boehringer Ingelheim, Dr Moroni-Zentgraf spent many years as a physician in Mainz, Germany where she first gained her passion for the management of respiratory disease and as an allergist, improving the lives of patients. Today Dr Moroni-Zentgraf lives in Sydney Australia with her husband and two dogs.


Dr Goslik Schepers Investment Manager, Brandon Capital Partners

Goslik Schepers joined Brandon Capital Partners in 2018 and has over 15 years’ experience in commercialisation and business development in industry and research commercialisation. Prior to joining Brandon Capital Partners, Dr Schepers was the GM of Business Development at Queensland’s largest medical research institute, QIMR Berghofer, where he managed a team in business development, commercialisation and pre-seed investment. In addition to academic research commercialisation at QIMR Berghofer, Oxford University and the University of Queensland, Dr Schepers also worked as VP Business Development at Alchemia Limited, Australia, and Summit PLC, United Kingdom for over 10 years combined. Dr Schepers holds a PhD in Molecular and Development Biology from the University of Queensland and is an alumnus of Melbourne University and James Cook University.

Brett Roberts Head of Strategic Partnerships, Novartis Australia

Brett Roberts is the Head of Strategic Partnerships at Novartis Australia. He brings a high energy, values driven approach to formulating and executing strategy which drives increased patient access to life changing medicine. Mr Roberts is the central filter and triage of academic and external innovation opportunities between the Australian research environment, the Novartis Institutes for Biomedical Research (NIBR) in Cambridge, MA, USA and Basel, Switzerland; and Novartis Australia.

Mr Roberts has international experience across Asia, the EU and USA; and cross-functional experience in Sales, Marketing; e-Commerce; Customer Service and Training functions across a wide range of industry namely: The Athlete’s Foot, Pfizer Australia, Hi-Fert, CellCare Australia, asap skin products and most recently Novartis where he has led the Novartis ANZ Diversity & Inclusion Council and is a current member of the Novartis Corporate Responsibility Taskforce.

Dr Shankar Subramanian Head of Academic Collaborations and Director of Global Alliance Management, AbbVie

Shankar Subramanian is Head of Academic Collaborations and Director of Global Alliance Management currently focusing on Academic and Early Stage Discovery Alliances. Dr Subramanian has been at AbbVie for 17 years in various marketing and commercial positions across various Divisions of Abbott. He gained global Marketing experience as the Marketing Director for Reductil at Abbott International prior to joining the Alliance Management group.

Dr Subramanian has held both Business Development and Alliance Management roles focusing mainly on Virology, Women’s Health and Oncology therapeutic areas. While he has successfully managed mid to late stage development assets from large Pharma partners and small Biotech alliances, his current focus is on building relationships with Academic alliances and early stage Discovery collaborations.

Prior to joining the Pharma Industry, Dr Subramanian had 10 years of operations and specialty chemical research experience in the Oil industry where he held patents on viscoelastic surfactants and launched commercial products to enhance the production of oil and gas wells. Dr Subramanian has a Ph.D in Organic Medicinal chemistry and an MBA.


Dr Ingmar Wahlqvist Investment Manager, Brandon Capital Partners

Ingmar Wahlqvist has been part of the investment team at Brandon Capital Partners, manager of the Medical Research Commercialisation Fund (MRCF), since 2009.

He began his professional career as a medical doctor, spending several years in clinical medicine before completing an MBA at Melbourne Business School. Thereafter he joined the Boston Consulting Group, serving clients in a variety of industries, including financial services, airlines, manufacturing and the public sector.

Feeling the pull of healthcare once more, he worked with several health-related start-up companies. Moving to France, he began at Sanofi, working in Commercial Operations, and in particular in the Cardiovascular Franchise of Global Marketing on Plavix, which during this time grew to be the 2nd-biggest selling drug in the world.

Returning to Australia, he joined Melbourne Ventures, commercialising technology from the University of Melbourne, a position which included a part-time secondment to GBS Venture Partners, before joining Brandon Capital.

Dr David Thomson External Affairs Manager, AbbVie

David Thomson has been employed at Abbvie since April 2016 and has responsibilities across a number of areas including government affairs, biological medicines policy and advocacy and innovation policy. He is an active member of the gastroenterology brand team.

Dr Thomson is a member of the AmCham Innovation Committee and Medicines Australia’s Biologics and Biosimilars Issues Group. Prior to joining AbbVie Dr Thomson worked for the Australian Government for three years in the Department of Industry, Innovation and Science and at the Department of Prime Minister and Cabinet, concentrating on innovation, venture capital and industry policy. He worked on both the National Industry Innovation and Competitiveness Agenda and the National Innovation and Science Agenda. Dr Thomson has a PhD from the University of Queensland with a project based on using bionanotechnology approaches to develop amplification-free viral load assays for resource limited environments.

William J Taranto President, Merck Global Health Innovation Fund, LLC // President, Merck Global Health Innovation Private Equity, LLC Vice President, Merck Global Health Innovation Group

William Taranto is the founder of GHI and is responsible for leading the GHI capability for Merck. The Merck Global Health Innovation Fund was established in late 2010 as a strategic response to the challenges surrounding Merck’s core business of discovering, developing and marketing innovative drugs and vaccines.

GHI deploys its evergreen $500 million fund focused on identifying opportunities that are adjacent to Merck’s core business of pharmaceuticals and vaccines. In the last five years, GHI has committed over $400 million across 35 portfolio companies. Some investments include Livongo Health, Navigating Cancer, Genome DX, Liaison Technologies, Caresync and Cleardata.

Mr. Taranto reports into the Chief Information Officer and President of Emerging Businesses. He is a member of the Merck Innovation Ventures Board, a group that manages the identification and funding of portfolio investments; and is also Chairman of the GHI Fund LLC Management Board. Mr. Taranto is also Chairman of the Board, Preventice Solutions Inc., Board Member Livongo Health, Board Member Global Corporate Venturing and Advisory Board Member Health XL.

Prior to joining Merck, Mr. Taranto spent 18 years at Johnson & Johnson in various marketing, sales and business development roles with increasing responsibility. In his previous position, VP, Health Care Strategy & Development, he was responsible for evaluating and creating new health care business models through venture capital and acquisitions. Mr. Taranto started his career as a sales representative for Janssen Pharmaceutica and progressed through various sales and marketing positions, including an assignment in Beerse, Belgium. Prior to joining J&J, Mr. Taranto spent eight years in investment banking. Mr. Taranto has a Bachelor of Business Administration from St. Bonaventure University.


Dr Martin Zagari Vice President, Global Health Economics, Amgen

Martin Zagari is Vice President of Global Health Economics at Amgen. In this role, he directs the planning, execution and scientific dissemination of worldwide economic and value evidence for Amgen’s entire product portfolio from early stage molecules to marketed products. Dr. Zagari joined Amgen in May of 2005.

Prior to Amgen, between 1997 and 2005, Dr. Zagari held various positions at Johnson & Johnson in Health Economics, Medical Affairs, and Strategic Marketing. These positions included: Executive Director in J&J Corporate Strategic Marketing for the erythropoietic agents, Medical Director for erythropoietic treatments in oncology at Ortho Biotech, and Director positions in Health Economics.

Between 1994 and 1997, Dr. Zagari worked in Health Economics and Outcomes consulting at Technology Assessment Group/Lewin-TAG, based in San Francisco.

Dr Zagari received his MD from Stanford University, an MBA from Rutgers University, and BS in Biology from the University of North Carolina at Chapel Hill and is trained in anesthesiology.

Dr Stewart Washer Executive Director, Zelda Therapeutics LTD

Stewart Washer has 25 years of CEO and Board experience in medical and agrifood biotech companies. He is currently the Executive Director of Zelda Therapeutics Ltd (ASX:ZLD) in the medicinal cannabis space, Chairman of Orthocell Ltd (ASX:OCC), a regenerative medicine company, Founding Chairman and current Director of Cynata Therapeutics Ltd (ASX:CYP) who are developing global stem cell therapies and Chairman of Minomic International Ltd with a novel approach to cancer diagnosis and treatment. Dr Washer is also a founder and consultant to AusCann Ltd (ASX:AC8), the largest medicinal cannabis company in Australia.

Dr Washer has held a number of Board positions in the past, including Chairman of Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a Director of iCeutica that was sold to a US Pharma. He was also a Senator with Murdoch University and was a Director of AusBiotech Ltd.

Gorjana MiticCommercialisation and Innovation Manager, Macquarie University

Marianne GillardPostdoctoral Researcher, University of Queensland

Jonathan NambiarVenture Capitalist, Magellan Asset Management

MENTORS BRIDGE PROGRAM 2018

Kamal DuaUniversity Academic Graduate School of Health, University of Technology Sydney

Katerina AleksoskaSector Policy management in Medtech and Pharmaceuticals / Department of Economic Development, Jobs, Transport and Resources

Cynthia CliffDirector (Knowledge Transfer and Partnership Development), Queensland University of Technology

THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram20182 0

P A R T I C I P A N T S

Gwen Allison Australian National University

Mark Anastasas Phylogica

Michael Andrews Luke Imunexus

Sarah Angus University of Technology Sydney

Anjaleena Anthony The University of Melbourne

Esther Apos Scidoc Solutions

Vasso Apostolopoulos Victoria University

Thomas Avery University of Adelaide

Sheila Barbero Griffith Hack

Anneke Blackburn Australian National University

Nathalie Bock Queensland University of Technology

Lilly Bojarski Bio-link Australia

Martin Boland Charles Darwin University

Yvonne Booth Uniquest Pty Ltd

Natalie Borg Monash University

Danny Bosch Microba

Joanne Bowen University of Adelaide

Benjamin Buckley University of Wollongong

Catalina Carrasco Pozo Griffith University

Tristan Chaplin University College London

Ann Choong Murdoch University

Michael Christie K&L Gates

MJ Chua Griffith Institute For Drug Discovery

Trudi Collet Queensland University of Technology

Claudio Counoupas University of Sydney

Ryan Cross WEHI Medical Research

Celine Deffrasnes Monash University

Jennifer Deuis University of Queensland

Prudence Donovan QIMR Berghofer Medical Research Institute

Christopher Draper-Joyce Monash University

Amanda Edgley The University of Melbourne

Jill Fernandes University of Queensland

Vivian Gleeson Burnet Institute

Dylan Glubb QIMR Berghofer Medical Research Institute

Gabrielle Goldberg Anaxis Pharma

Nagaraj Gopisetty Translational Research Institute

Andrew Groth University of Technology Sydney

Lynette Hogan Monash University

Lieven Huang Peter MacCallum Cancer Centre

Varinder Jeet University of Queensland

Charlene Kahler The University of Western Australia

Eloise Keeffe Griffith University

Roy Chze Khai Kong The University of Melbourne

Willian Korim Florey Institute of Neuroscience and Mental Health

Christina Kulis University of Queensland

Andreas Kupz James Cook University

Celine Latouche Baker Heart And Diabetes Institute

Melvin Lee Australia China Technology Incubator Pty Ltd

Greg Leong The University of Melbourne

Willem Joost Lesterhuis The University of Western Australia

Ruohan Li The University of Western Australia

THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018 2 1

P A R T I C I P A N T S

Mana Liao Garvan Institute of Medical Research

Kate Lingard QBiotics

Michelle Liu QIMR Berghofer Medical Research Institute

Kathleen Luders Flinders University

Kate Mackin Hudson Institute of Medical Research

Paul Madge QIMR Berghofer Medical Research Institute

Maretta Mann Griffith University

Martina Mariano Harry Perkins Institute of Medical Research

Laure Martine Ellume

Nicholas Matovic Uniquest Pty Limited

Andrew Milligan The Cooperative Research Centre for Cell Therapy Manufacturing

Raisa Monteiro Griffith University

Clare Morgan The Walter & Eliza Hall Institute of Medical Research

Rachel Mudge Jean Hailes - For Women’s Health

Annabella Newton Phillips Ormonde Fitzpatrick

Russell Nicholls Curtin University

Lauren Nicotra Bionomics Limited

Sheona Page University of The Sunshine Coast

Christos Papadimitriou Bio-link Australia

Michelle Papadimitriou OccuRx Pty Ltd

Brighid Pappin Hostplus

Jef Pennings University of Wollongong

Cris Popp Grunbiotics

Stephen Proksch Curtin University

Tifelle Reisinger Domainex

Derek Richard Queensland University of Technology

Jack Ryan CSIRO

Jerome Sarris Western Sydney University

Andrew Scholey Swinburne University

Fiona Simpson The University of Melbourne

Edmond Sorich Glia Diagnostics

Anubhav Srivastava Monash Institute of Pharmaceutical Sciences

Grant Stuchbury Uniquest Pty Limited

Kathryn Sunn University of Sydney

Shereen Tan The University of Melbourne

JC Tan UniSA Ventures

Evelin Tiralongo Griffith University

Joe Tiralongo Griffith University

Mabel Tsui Australian Government

Steve Turner QIMR Berghofer Medical Research Institute

Fabrice Turpin The University Of Queensland

Meggie Voogt QIMR Berghofer Medical Research Institute

David Wibowo Griffith Institute For Drug Discovery

Charlotte Williams CSIRO

Kunsala Yapa ERA Consulting (Australia)

Bo Yun Peter MacCallum Cancer Centre

Lin Zhang Moyi Health Tech

BRIDGE PROGRAM SYMPOSIUMTHE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram20182 2 THE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram20182 2

NOTES

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NOTESTHE BRIDGE PROGRAM // R E S I D E N T I A L T R A I N I N G // #Br idgeProgram2018 2 3

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

The Bridge Program has received industry-matched funding through the MTPConnect Project Fund Program – investing in ideas to improve the productivity, competitiveness and innovative capacity of Australia’s medtech,

biotech and pharmaceutical sector.

S U P P O R T E D B Y

residential training - qut · the bridge prgram // residential training // #bridgeprogram2018 7 dr...

Documents